BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.440
-0.010 (-0.69%)
At close: May 19, 2025, 4:00 PM
1.450
+0.010 (0.69%)
After-hours: May 19, 2025, 6:28 PM EDT
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -95.65% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for BioXcel Therapeutics stock ranges from a low of $4.00 to a high of $80. The average analyst price target of $42.6 forecasts a 2,858.33% increase in the stock price over the next year.
Price Target: $42.60 (+2,858.33%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 19, 2025.
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +4,413.89% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $48 | Strong Buy | Maintains | $80 → $48 | +3,233.33% | Jan 30, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $112 → $4 | Strong Buy → Sell | Downgrades | $112 → $4 | +177.78% | Jan 7, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $112 → $80 | Strong Buy | Maintains | $112 → $80 | +5,455.56% | Jan 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $112 → $80 | Strong Buy | Maintains | $112 → $80 | +5,455.56% | Oct 21, 2024 |
Financial Forecast
Revenue This Year
2.88M
from 2.27M
Increased by 27.23%
Revenue Next Year
9.16M
from 2.88M
Increased by 217.72%
EPS This Year
-17.67
from -23.51
EPS Next Year
-11.67
from -17.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.0M | 24.5M | 114.9M | ||
| Avg | 2.9M | 9.2M | 49.3M | ||
| Low | 1.5M | 3.1M | 10.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 122.4% | 749.7% | 1,154.0% | ||
| Avg | 27.2% | 217.7% | 438.2% | ||
| Low | -35.1% | 8.8% | 13.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -8.23 | -7.47 | -2.52 | ||
| Avg | -17.67 | -11.67 | -6.11 | ||
| Low | -31.93 | -17.73 | -8.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.